MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Archives & Legacy
*Organization & Developments: Progenics (Archives 2015-2017)
Parents
Archives & Legacy
Organization & Developments: Progenics
Children
2015: Upcoming catalysts for PGNX are the approval of oral RELISTOR (which is out-licensed to Salix) and completion of Azedra trial and potential NDA filing for the drug.
2016: Can 'Santa Claus' Rally Continue For These 3 Small Biotechs? - Portola, Synergy, Progenics
2017 Progenics Is Starting To Look Interesting Again - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
2017: A Key Week Ahead For Progenics Pharmaceuticals - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
2017: Biotech Forum Daily Digest: Behind Ocular's Fall; Revisiting Progenics
2017: Biotech Forum Daily Digest: Revisiting Progenics After Manufacturing Delay
2017: Progenics and Sarepta_These Rare Disease Biotechs Could Make Enticing Buyout Targets
2017: Progenics: Dynavax 2.0? - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
2017: Progenics: The Successful Trial That (Some Claim) Has Failed - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
2017: Relistor was first approved in 2008 for the treatment of opioid-induced constipation
2017: The company currently has one product on the market, Relistor